Prosper Health Raises $10M: Inside the Weston, FL Adult Autism Telehealth Startup's Funding History

Prosper Health, a telehealth startup based in Weston, Florida that diagnoses and treats autistic adults, sold $10 million in equity to six accredited investors in a raise that closed August 28, 2026 — its second disclosed round in 19 months.

The Weston-based company, founded in 2023 by CEO Benjamin Schecter, first disclosed the new capital in an SEC Form D filing dated September 10, 2026, and Behavioral Health Business reported the raise on September 15, 2026. It follows a $16.2 million round in January 2025 that brought in Maverick Ventures, Kindred Ventures, Spice Capital, BoxGroup, and Haystack Fund — putting Prosper Health's disclosed total funding at roughly $26.2 million. You can track other South Florida rounds like this one on the South Florida funding tracker.

What Does Prosper Health Actually Do?

Prosper Health provides virtual autism diagnostic assessments and individual outpatient talk therapy exclusively for autistic and neurodivergent adults, a narrower focus than most behavioral health platforms, which are built primarily around pediatric autism intervention. The company's bet is that a large population of adults went undiagnosed as children — either because autism was more narrowly defined decades ago or because access to diagnostic centers was limited — and now need both a diagnosis and ongoing therapy designed around an adult population rather than a pediatric one.

Prosper Health's Funding History, Round by Round

Source: Behavioral Health Business (Jan 23, 2025 and Sept 15, 2026); SEC Form D filing dated Sept 10, 2026. Neither round disclosed a post-money valuation.

How Does Prosper Health's Raise Compare to Other Autism-Care Startups?

Prosper Health's two rounds sit inside a broader run of venture money into autism care over the past 19 months. Frontera Health, an AI-backed autism therapy startup, raised $32 million in February 2025, roughly three weeks after Prosper Health's own January 2025 round — most of that money going toward pediatric applied behavior analysis (ABA) rather than Prosper Health's adult-only focus, but drawing from the same investor thesis that autism care is underbuilt relative to demand.

Why Adult Autism Diagnosis Is a Real Access Gap, Not Just a Pitch-Deck Stat

The CDC's most recent modeled estimate puts autism prevalence among U.S. adults at 2.21%, or roughly 5.4 million people, using 2017 data across ages 18-84 and including both diagnosed and estimated undiagnosed cases. Most of that population grew up under a narrower clinical definition of autism than exists today, and access to a first diagnosis in adulthood is genuinely constrained: a Centers for Medicare and Medicaid Services survey of U.S. autism diagnostic centers found nearly two-thirds had wait times longer than four months, with 14% exceeding a full year. That access gap — not a novel drug or device — is the core bet behind Prosper Health's model: a virtual-first format can route around a wait-list-constrained, pediatric-oriented diagnostic system faster than building more brick-and-mortar clinics can.

Where the Thesis Could Break

Neither of Prosper Health's rounds disclosed a valuation, which makes it impossible to judge whether the company is being priced up, down, or flat between raises — a meaningfully different situation from a startup that reports a stated post-money figure each round. The August 2026 filing also lists no named investors, unlike the January 2025 round's five-firm syndicate, which could simply reflect existing investors doubling down without a new lead, or could signal a harder time attracting new institutional capital at this stage; the filing alone doesn't distinguish between the two. More broadly, adult autism telehealth is a category with real reimbursement complexity — insurance coverage for adult autism diagnosis and therapy varies significantly by state and payer, and a virtual-first model still has to prove it can convert diagnostic assessments into sustained, reimbursed therapy relationships rather than one-time evaluations.

The Bottom Line

Prosper Health's $10 million raise is a real, SEC-verified equity sale, not a rumor or a rounded-up estimate — the $10,029,002 figure matches exactly between the company's own Form D filing and Behavioral Health Business's reporting. What it doesn't tell us is whether the Weston-based company is scaling toward the kind of institutional Series B that its January 2025 syndicate might have signaled, or whether the undisclosed, unnamed structure of this second raise reflects a quieter bridge. Either way, it's a genuine South Florida healthtech data point in a sector — adult autism diagnosis and care — that has real, CDC-documented demand behind it.